LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02186 LUYE PHARMA

Closed The day following Ching Ming Festival 04-02 16:08:21

2.920

+0.210

+7.75%

High2.980	Low2.660	Vol170.86M
Open2.700	D1 Closing2.710	Amplitude11.81%
Mkt Cap11.67B	Tradable Cap11.67B	Total Shares4.00B
T/O488.03M	T/O Rate4.28%	Tradable Shares4.00B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02186","market":"HK","secType":"STK","nameCN":"LUYE PHARMA","latestPrice":2.92,"timestamp":1775117301004,"preClose":2.71,"halted":0,"volume":170858000,"delay":0,"changeRate":0.07749077490774907,"floatShares":3995000000,"shares":3995000000,"eps":0.125445,"marketStatus":"Closed The day following Ching Ming Festival","change":0.21,"latestTime":"04-02 16:08:21","open":2.7,"high":2.98,"low":2.66,"amount":488030944,"amplitude":0.118081,"askPrice":2.92,"askSize":841500,"bidPrice":2.91,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":0.172,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":1404835200000,"exchange":"SEHK","adjPreClose":2.71,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":4.813362406560685,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02186","defaultTab":"news","newsList":[{"id":"2625629416","title":"Undiscovered Gems In Asia Including 3 Promising Small Cap Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2625629416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625629416?lang=en_us&edition=fundamental","pubTime":"2026-04-06 06:02","pubTimestamp":1775426578,"startTime":"0","endTime":"0","summary":"As global markets navigate geopolitical tensions and energy market volatility, Asian small-cap stocks are drawing attention for their potential amidst these dynamic conditions. With improving domestic activity signals in China and strategic economic maneuvers in India, the region presents unique opportunities for investors seeking growth beyond the traditional large-cap landscape. Identifying promising small-cap stocks involves looking at companies that demonstrate resilience and adaptability...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/4012000-choice2-main-header/1585186808051","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4012000-choice2-main-header/1585186808051"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/cn/automobiles/szse-301225/hengbo-holdingsltd-shares/news/undiscovered-gems-in-asia-including-3-promising-small-cap-st","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/cn/automobiles/szse-301225/hengbo-holdingsltd-shares/news/undiscovered-gems-in-asia-including-3-promising-small-cap-st","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02186","BK1191","BK1606","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625150576","title":"Luye Pharma Group (SEHK:2186) Valuation After Earnings Growth And Surprise 2025 Dividend Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2625150576","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625150576?lang=en_us&edition=fundamental","pubTime":"2026-04-04 22:18","pubTimestamp":1775312322,"startTime":"0","endTime":"0","summary":"Why Luye Pharma’s latest earnings matter for investors\nLuye Pharma Group (SEHK:2186) has drawn fresh attention after reporting its full year 2025 results, with higher sales and net income alongside a decision not to declare a 2025 dividend.\nThe company reported sales of CN¥6,308.37 million for 2025, compared with CN¥6,061.44 million a year earlier. Net income came in at CN¥618.75 million, up from CN¥471.89 million, while basic earnings per share from continuing operations were CN¥0.1588...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2186/luye-pharma-group-shares/news/luye-pharma-group-sehk2186-valuation-after-earnings-growth-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1191","BK1606","BK1583","02186","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167334961","title":"Stock Track | LUYE PHARMA Stock Soars 5.17% in Intraday Trading After Reporting Strong 2025 Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1167334961","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167334961?lang=en_us&edition=fundamental","pubTime":"2026-04-02 10:01","pubTimestamp":1775095310,"startTime":"0","endTime":"0","summary":"LUYE PHARMA's stock surged 5.17% during intraday trading on Thursday, reflecting strong investor sentiment.The sharp rise follows the company's release of its 2025 earnings report, which showed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141323222","title":"LUYE PHARMA Shares Surge Nearly 5% on Strong 2025 Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1141323222","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141323222?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:59","pubTimestamp":1775095162,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) rose nearly 5% in Hong Kong trading. At the time of writing, the stock was up 3.69% to HK$2.81, with a trading volume of HK$105 million. The catalyst for the movement was the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4588","VXUS","BK4585","BK1606","BK1191","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623379597","title":"Luye Pharma Group Books 31% Profit Growth in 2025; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623379597","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623379597?lang=en_us&edition=fundamental","pubTime":"2026-03-31 10:18","pubTimestamp":1774923480,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  booked 618.7 million yuan in attributable profit for 2025, rising 31% from 471.9 million yuan in 2024, according to a Hong Kong bourse filing Tuesday.Earnings per share were 0.1250 yuan, compared with 0.1254 yuan in the prior year.Revenue rose 4.1% year on year to 6.31 billion yuan, figures showed.The company did not declare a final dividend for the year.Shares of the company were up nearly 3% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02186","BK1606","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623359376","title":"BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2623359376","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623359376?lang=en_us&edition=fundamental","pubTime":"2026-03-31 09:40","pubTimestamp":1774921232,"startTime":"0","endTime":"0","summary":"BRIEF-Luye Pharma Group Posts FY Net Income Attributable RMB618.7 MLNMarch 31 (Reuters) - Luye Pharma 2186.HK: LUYE PHARMA GROUP FY NET INCOME ATTRIBUTABLE RMB 618.7 MILLIONLUYE PHARMA GROUP FY REVENUE RMB 6,308.4 MILLIONFurther company coverage: [ ] ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXB82ACC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","02186","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103471263","title":"Luye Pharma 2025 Net Profit Up 9.4% to RMB705.70 Million as Oncology and CNS Sales Accelerate","url":"https://stock-news.laohu8.com/highlight/detail?id=1103471263","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103471263?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:45","pubTimestamp":1774910728,"startTime":"0","endTime":"0","summary":"Luye Pharma (02186) reported 2025 revenue of RMB6.31 billion, a 4.1% year-on-year increase. Net profit rose 9.4% to RMB705.70 million, while profit attributable to shareholders advanced 31.1% to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623463322","title":"Luye Pharma Group FY Net Income Attributable RMB 618.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623463322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623463322?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:30","pubTimestamp":1774909853,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLXB82ACC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02186","BK1583","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623032245","title":"Luye Pharma Group FY Revenue RMB 6,308.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623032245","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623032245?lang=en_us&edition=fundamental","pubTime":"2026-03-31 06:30","pubTimestamp":1774909853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nPLXB82ACC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","BK1191","BK1583","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623341913","title":"Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623341913","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623341913?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:00","pubTimestamp":1774882833,"startTime":"0","endTime":"0","summary":"Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.Selling and distribution expenses climbed to RMB 340.9 million, while R&D costs edged down to RMB 147.6 million.Business updates highlighted two new China launches, Boyouping  in August and Boyoujing  in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely respons","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5HctGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0209","BK0184","601607","BK0196","BK1161","BK0099","BK0012","BK0175","BK0020","BK1583","BK1606","06955","BK1191","BK0097","BK0028","BK0187","BK0188","BK0183","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115727058","title":"LUYE PHARMA (02186) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1115727058","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115727058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:40","pubTimestamp":1773754838,"startTime":"0","endTime":"0","summary":"LUYE PHARMA GROUP LTD. (Stock Code: 02186) has scheduled a board meeting for 30 March 2026. The agenda includes: 1. Approval and publication of the consolidated annual results for the fiscal year...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169465343","title":"LUYE PHARMA (02186) Monthly Return Announcement for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1169465343","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169465343?lang=en_us&edition=fundamental","pubTime":"2026-03-05 17:35","pubTimestamp":1772703305,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) released its monthly return for equity securities as of 28 February 2026. The authorized share capital remains 10.00 billion ordinary shares with a par value of USD 0.02,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102637067","title":"Luye Pharma Group Ltd. (02186) Announces January 2026 Monthly Return on Movements in Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=1102637067","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102637067?lang=en_us&edition=fundamental","pubTime":"2026-02-05 18:05","pubTimestamp":1770285921,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. (02186) released its Monthly Return on Movements in Securities for January 2026. As of January 31, 2026, the company’s authorized share capital remained at 10,000,000,000...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606279121","title":"China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2606279121","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606279121?lang=en_us&edition=fundamental","pubTime":"2026-01-27 11:07","pubTimestamp":1769483273,"startTime":"0","endTime":"0","summary":"Two China Cinda Asset Management (HKG:1359) subsidiaries will inject 285 million yuan into Luye Pharma's (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1606","BK1191","01359","BK1156","BK1583","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141447932","title":"LUYE PHARMA (02186) Shareholder Transfers HK$454 Million Worth of Shares from CCB International Securities to UBS Securities Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1141447932","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141447932?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:58","pubTimestamp":1769475499,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange data reveals that on January 26, a shareholder of LUYE PHARMA (02186) transferred shares from CCB International Securities to UBS Securities Hong Kong Limited. The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","BK1606","161027","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189026194","title":"LUYE PHARMA (02186): Nanjing LUYE Pharma Secures RMB 285 Million Capital Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1189026194","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189026194?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:17","pubTimestamp":1769469466,"startTime":"0","endTime":"0","summary":"LUYE PHARMA (02186) announced that on January 26, 2026, Shenzhen LUYE, Nanjing Xinshi, Nanjing Xin'an, Ningbo Xinda, and Nanjing LUYE entered into a capital injection agreement. Under this agreement,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","BK1583","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140354691","title":"Luye Pharma (02186) Announces RMB285 Million Capital Injection in Nanjing Luye, Triggering Discloseable and Connected Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1140354691","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140354691?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:04","pubTimestamp":1769468649,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. (02186) announced that on 26 January 2026, Shenzhen Luye, NJ Xinshi, Nanjing Xinan, Ningbo Cinda, and Nanjing Luye entered into agreements for a capital injection totaling...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606224170","title":"Luye Pharma - Nanjing Xinan, Ningbo Cinda to Provide Further Capital to Nanjing Luye for Total RMB285 Mln on Jan 26","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224170","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224170?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:02","pubTimestamp":1769468523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02186","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606224902","title":"Luye Pharma Completes Transfer of 25% Stake in Nanjing Luye to NJ Xinshi","url":"https://stock-news.laohu8.com/highlight/detail?id=2606224902","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606224902?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:00","pubTimestamp":1769468445,"startTime":"0","endTime":"0","summary":"Luye Pharma Group Ltd. has completed the transfer of a 25% equity interest in its subsidiary, Nanjing Luye, to NJ Xinshi. Following the completion of the transaction on 19 January 2026, Nanjing Luye is now owned 75% by Luye Pharma Group and 25% by NJ Xinshi. The company stated that the partnership agreement and related transactions allow the Group to maintain control over the identity of Nanjing Luye’s partner, supporting continuity, governance stability, and alignment of strategic objectives.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luye Pharma Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 26, 2026, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL1b7LG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","02186","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606245438","title":"Shandong Boan Biotechnology Transfers 11.99 Million H Shares to Complete Minority Stake Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2606245438","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606245438?lang=en_us&edition=fundamental","pubTime":"2026-01-26 22:01","pubTimestamp":1769436073,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotechnology Co. Ltd. has announced that its controlling shareholder, Luye Pharma Group Ltd., through its wholly-owned subsidiary Shandong Luye Pharmaceutical Co., Ltd., will transfer 11,986,600 H shares of Boan Biotechnology to the Issuer on 27 January 2026. This transfer is part of the completion of a previously announced proposed transfer, in accordance with the terms of a subscription agreement related to Exchangeable Preference Shares. The board of Boan Biotechnology does not expect the transaction to have any material adverse effect on the group’s business operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief v","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLbl2mT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","06955","BK1161","02186","BK1606","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luye.cn","stockEarnings":[{"period":"1week","weight":0.2641},{"period":"1month","weight":0.2066},{"period":"3month","weight":0.0542},{"period":"6month","weight":-0.1609},{"period":"1year","weight":0.3394},{"period":"ytd","weight":0.0657}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Luye Pharma Group Ltd is a company mainly engaged in developing, producing, marketing and selling pharmaceutical products. The Company operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.024212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.016158},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.022436},{"month":4,"riseRate":0.5,"avgChangeRate":0.005165},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.0086},{"month":6,"riseRate":0.363636,"avgChangeRate":0.035296},{"month":7,"riseRate":0.636364,"avgChangeRate":0.018026},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.044846},{"month":9,"riseRate":0.583333,"avgChangeRate":0.045957},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00637},{"month":11,"riseRate":0.5,"avgChangeRate":0.024651},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.012685}],"exchange":"SEHK","name":"LUYE PHARMA","nameEN":"LUYE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUYE PHARMA,02186,LUYE PHARMA股票,LUYE PHARMA股票老虎,LUYE PHARMA股票老虎国际,LUYE PHARMA行情,LUYE PHARMA股票行情,LUYE PHARMA股价,LUYE PHARMA股市,LUYE PHARMA股票价格,LUYE PHARMA股票交易,LUYE PHARMA股票购买,LUYE PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUYE PHARMA(02186),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUYE PHARMA(02186) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}